Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience

Allogene Therapeutics, Inc.

Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.
Allogene relies on Cellectis's TALEN technology for allogeneic CAR T candidates including cema-cel and ALLO-316.
Cellectis notified Allogene on October 6, 2025, and intends to vigorously defend against the claims.
Factor may also assert direct claims against Allogene as a commercial user of the disputed technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.